Please use this identifier to cite or link to this item:
Title: Safety of macrolides during pregnancy
Authors: Lin, K.J.
Mitchell, A.A.
Yau, W.-P. 
Louik, C.
Hernández-Díaz, S.
Keywords: azithromycin
congenital malformations
Issue Date: Mar-2013
Citation: Lin, K.J., Mitchell, A.A., Yau, W.-P., Louik, C., Hernández-Díaz, S. (2013-03). Safety of macrolides during pregnancy. American Journal of Obstetrics and Gynecology 208 (3) : 221e1-221e8. ScholarBank@NUS Repository.
Abstract: Objective: Prior studies have reported increased risks of congenital heart defects (CHD) and pyloric stenosis (PS) after prenatal exposure to macrolide antibiotics. We sought to assess the association between maternal use of erythromycin and nonerythromycin macrolides and the risks of CHD and PS. Study Design: Among participants in the Slone Epidemiology Center Birth Defects Study from 1994 through 2008, we identified 4132 infants with CHD and 735 with PS as cases, and 6952 infants without any malformation as controls. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with use of erythromycin or nonerythromycin macrolides in each trimester using conditional logistic regression and adjusting for risk factors for CHD and PS, fever, specific types of infections, and their associated treatments. Results: During the first trimester, 0.4% and 0.7% of control women had used erythromycin and nonerythromycin macrolides, respectively. Compared to non-use during pregnancy, first-trimester exposure to erythromycin was not associated with an increased risk of CHD (OR, 1.3; 95% CI, 0.6-2.6) or PS (OR, 0.9; 95% CI, 0.3-3.0). The corresponding ORs for nonerythromycin macrolides were 0.7 (95% CI, 0.4-1.3) for CHD and 1.7 (95% CI, 0.6-4.6) for PS. We found no association between third-trimester exposure to erythromycin or nonerythromycin macrolides and the risk of PS. Hypothesis generation analyses did not identify appreciable associations between maternal use of macrolides and other common specific birth defects. Conclusion: We found no meaningful associations between the risks of CHD, PS, and other common malformations in relation to use of macrolides in pregnancy. © 2013 Mosby, Inc.
Source Title: American Journal of Obstetrics and Gynecology
ISSN: 00029378
DOI: 10.1016/j.ajog.2012.12.023
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Jan 13, 2021


checked on Jan 13, 2021

Page view(s)

checked on Jan 17, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.